Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019

Conference Call Scheduled for Monday, August 5, 2019 at 4:30 p.m. ET

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will release second quarter 2019 financial results on Monday, August 5, 2019 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT/4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.

Individuals interested in listening to the conference call may do so by dialing [phone] for domestic callers, or [phone] for international callers and reference conference ID: 9260859; or from the webcast link in the investor relations section of the company’s website at: www.revance.com.

A replay of the call will be available beginning August 5, 2019 at 4:30 p.m. PT/7:30 p.m. ET to August 6, 2019 at 4:30 p.m. PT/7:30 p.m. ET. To access the replay, dial [phone] or [phone] and reference conference ID: 9260859. The webcast will be available in the investor relations section on the company's website for 30 days following the completion of the call.

About Revance Therapeutics, Inc.

Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering new innovations in neuromodulators for aesthetic and therapeutic indications. Revance’s lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines, delivering unprecedented efficacy and long-lasting duration of effect, and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DAXI in forehead lines and lateral canthal lines (crow’s feet), as well as in three therapeutic indications - cervical dystonia, adult upper limb spasticity and plantar fasciitis, with plans to study migraine. Beyond DAXI, Revance has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

BOTOX® is a registered trademark of Allergan, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190729005635/en/

INVESTORS Revance Therapeutics, Inc.: Jeanie Herbert, 714-325-3584 [e-mail] or Gilmartin Group, LLC.: Laurence Watts, 619-916-7620 [e-mail]

MEDIA Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476 [e-mail] or General Media: Y&R: Jenifer Slaw, 347-971-0906 [e-mail] or Trade Media: Nadine Tosk, 504-453-8344 [e-mail]